Regeneron plans to develop antibodies to protect against the Omicron variant, as its current cocktail has diminished efficacy against it. The company expects to start clinical trials on the new antibodies at the beginning of 2022. (CNBC Weekly)

Horizon Therapeutics announced a $1.5 billion partnership with Alpine Immune Sciences. Horizon will assume development and commercialization costs once Alpine develops its molecules to preclinical milestones. (Endpoints News)

Biogen will start a large clinical trial in May 2022 to further examine the efficacy of its Alzheimer’s drug Aduhelm, the company said Thursday. Conducting the trial, which is set to enroll some 1,300 participants with early-stage Alzheimer’s, was a condition of the Food and Drug Administration’s approval. (STAT)

Demand for COVID-19 tests could triple if an expected winter surge hits, the U.S. Health and Human Services Department predicted. The agency expects Omicron to become the dominant strain in the U.S. within a month. (Politico)

Tens of millions of refugees may not have access to COVID-19 vaccines due to legal liability issues. Many vaccine makers have required nations to indemnify them for any adverse events caused by the vaccine, but millions of refugees aren’t covered by the vaccine efforts of national governments. (Reuters)